All articles by RanjithKumar Dharma

RanjithKumar Dharma

Aulos to begin Phase II portion of solid tumour therapy trial

The first Phase II expansion cohorts will concentrate on renal cell carcinoma and melanoma.

MyMD to begin Phase II trial of rheumatoid arthritis therapy

The placebo-controlled and randomised study is anticipated to enrol around 60 patients with active RA.

Alentis doses first subject in organ fibrosis therapy trial

The trial intends to recruit subjects with ANCA-RPGN, a severe and potentially fatal disease.

280Bio doses first subject in oral RAS signalling inhibitor trial

TEB-17231 has shown potent inhibition of tumour cell proliferation in vivo and in vitro in preclinical research.

SciNeuro concludes dosing in study of Alzheimer’s therapeutic

The study will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of the therapy in healthy subjects.

Neurogene doses two paediatric patients in trial of Rett Syndrome therapy

The company plans to administer the dose to a third patient early next year.

Acadia starts Phase III study of PWS therapy

Change from baseline to week 12 on the HQ-CT score is the study’s primary efficacy endpoint.

Vaxxas reports positive data from MR vaccine trial

Using the data from this study, the company is moving forward with a Phase I/II clinical trial in the Gambia, Africa.

SciSparc begins clinical trial of ASD therapy

The SCI-210 therapy combines cannabidiol and SciSparc’s Palmitoylethanolamide, designed to reduce autism spectrum disorder (ASD) symptoms.

Medicure approved to enrol patients in paediatric disease trial

The trial will enrol around ten patients at sites in Australia and the US.